Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2020.07.023
Abstract: Objective The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). Methods Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab)… read more here.
Keywords: administration; stage iib; disease; mortality ... See more keywords